Characterization of the therapeutic effect of antibodies targeting the Ebola glycoprotein using a novel BSL2-compliant rVSVΔG-EBOV-GP infection model

• Published in: Emerging microbes & infections 2021-01, Vol.10 (1), p.2076-2089
• Main Authors: Lee, Ha-Na, McWilliams, Ian L., Lewkowicz, Aaron P., Engel, Kaliroi, Ireland, Derek D. C., Kelley-Baker, Logan, Thacker, Seth, Piccardo, Pedro, Manangeeswaran, Mohanraj, Verthelyi, Daniela
• Format: Article
• Language: English
• Subjects: Animals; Antibodies, Monoclonal - administration & dosage; Antibodies, Neutralizing - administration & dosage; Antibodies, Viral - administration & dosage; BASIC BIOLOGICAL SCIENCES; BSL-2 model; CNS infection; Disease Models, Animal; Ebola virus; Ebola virus (EBOV); Ebolavirus - genetics; Ebolavirus - immunology; Ebolavirus - physiology; EBOV; EBOV glycoprotein; EBOV glycoprotein (EBOV-GP); EBOV-GP; EBOV-GP pseudotyped vesicular stomatitis virus; EBOV-GP pseudotyped vesicular stomatitis virus (VSV-EBOV); Hemorrhagic Fever, Ebola - drug therapy; Hemorrhagic Fever, Ebola - virology; Humans; meningoencephalitis; Mice; Mice, Inbred C57BL; SAB-139; Vesicular stomatitis Indiana virus - genetics; Vesicular stomatitis Indiana virus - physiology; Viral Envelope Proteins - genetics; Viral Envelope Proteins - immunology; VSV-EBOV
• ISSN: 2222-1751; 2222-1751
• DOI: 10.1080/22221751.2021.1997075

Ebola virus (EBOV) infections cause haemorrhagic fever, multi-organ failure and death, and survivors can experience neurological sequelae. Licensing of monoclonal antibodies targeting EBOV glycoprotein (EBOV-GP) improved its prognosis, however, this treatment is primarily effective during early stages of disease and its effectiveness in reducing neurological sequela remains unknown. Currently, the need for BSL4 containment hinders research and therapeutic development; development of an accessible BSL-2 in vivo mouse model would facilitate preclinical studies to screen and select therapeutics. Previously, we have shown that a subcutaneous inoculation with replicating EBOV-GP pseudotyped vesicular stomatitis virus (rVSVΔG-EBOV-GP or VSV-EBOV) in neonatal mice causes transient viremia and infection of the mid and posterior brain resulting in overt neurological symptoms and death. Here, we demonstrate that the model can be used to test therapeutics that target the EBOV-GP, by using an anti-EBOV-GP therapeutic (SAB-139) previously shown to block EBOV infection in mice and primates. We show that SAB-139 treatment decreases the severity of neurological symptoms and improves survival when administered before (1 day prior to infection) or up to 3 dpi, by which time animals have high virus titres in their brains. Improved survival was associated with reduced viral titres, microglia loss, cellular infiltration/activation, and inflammatory responses in the brain. Interestingly, SAB-139 treatment significantly reduced the severe VSV-EBOV-induced long-term neurological sequalae although convalescent mice showed modest evidence of abnormal fear responses. Together, these data suggest that the neonatal VSV-EBOV infection system can be used to facilitate assessment of therapeutics targeting EBOV-GP in the preclinical setting.